The chromatographic capacity factors (k IAM ) of 23 structurally diverse drugs were measured by the immobilized artificial membrane (IAM) phosphatidylcholine chromatography for the prediction of blood-brain barrier (BBB) penetration. The k IAM was determined using the mobile phase consisting of acetonitrile:DPBS (20:80 v/v) and corrected for the molar volume of the solutes (k IAM /MW n ). The correlation between k IAM /MW n and CNS penetration was highest when measured at pH 5.5 with the power function of n = 4. This in vitro prediction method was validated with 7 newly synthesized PDE-4 inhibitors. The relationship between in vivo plasma-to-brain concentration ratios and in vitro CNS penetration was excellent (r = 0.959). The developed in vitro prediction method may be used as a rapid screening tool for BBB penetration of drugs with passive transport mechanism, with high success, low cost, and reproducibility. (Journal of Biomolecular
INTRODUCTION
T HE CONTINUOUS LAYER of the brain endothelium lining capillaries is commonly called the blood-brain barrier (BBB) and acts as a barrier for drugs entering the CNS. The penetration of hydrophilic drugs into the brain is restricted by the presence of the BBB. Nevertheless, lipophilic drugs including CNS-targeted drugs may enter the brain by transcellular passive diffusion. Some drugs may also cross the BBB by active processes, involving influx (e.g., amino acids) and efflux (e.g., P-glycoprotein, multidrugresistant proteins) transporters. 1, 2 In drug discovery for CNS active drugs, it is important to determine whether a candidate molecule is capable of penetrating the BBB. For drugs targeted at the CNS, the BBB penetration is a necessity, whereas for drugs acting in peripheral tissues, the BBB penetration may lead to undesirable adverse effects. 3, 4 The BBB penetration potential of drug candidates may be assessed by various in silico, in vivo, and in vitro methods. In silico approaches include the determination of physicochemical properties such as octanol-water partition coefficient (log P), 5 hydrogen-bonding potential (∆ log P), 6 molecular polar surface area (PSA), 7 linear free energy, 8, 9 and surface tension. 10, 11 In vivo biological approaches include microdialysis, 12, 13 cerebrospinal fluid sampling, 12, 14 autoradiography, 15 nuclear magnetic resonance, 16 and positron emission spectroscopy. 17 In vitro methods use isolated brain capillaries 18 and cultured cells such as bovine brain microvessel endothelial cells, 19 brain capillary endothelial cells, 20 mouse brain endothelial cells 4, 21 and Caco-2 cells. 22 Other in vitro approaches of the parallel artificial membrane permeability assay (PAMPA) 23 and the immobilized artificial membrane (IAM) chromatographicy 24, 25 have been reported. These latter approaches are based on artificial membrane-mimic systems and may offer the advantages of experimental simplicity over the cultured cell permeability test, without requiring cell culture cycles. The PAMPA requires a membrane permeability experiment through artificial membranes, 26 whereas the IAM chromatographic assay is based on the solute interaction with IAMs. 27 The IAM chromatography has been used in predicting the drug transport across biological barriers. 25, 26, 28 This study examined the utility of the IAM phosphatidylcholine column chromatography for the prediction of BBB penetration potential using a set of 23 structurally unrelated drugs. The developed method was validated for a set of 7 newly synthesized PDE-4 inhibitors. The findings of this study suggest that the IAM chromatography may be used as a rapid screening method for the prediction of BBB permeation.
Shimadzu high-performance liquid chromatography system (Tokyo, Japan) consisting of a model SPD-10A UV-Vis detector, SCL-10A system controller, LC-10AT pump, SIL-10A autosampler, and CTO-10A column oven was used in the assay. The analytical column was an IAM.PC.DD column (4.6 mm i.d. × 10 cm length, particle size 5 µm, pore size 300 Å) purchased from Regis Technologies (Morton Grove, IL). The mobile phase was a mixture of acetonitrile and DPBS (20:80 v/v) with pH adjusted to 5.5 and 7.0 using HCl. The flow rate of the mobile phase was maintained at 0.5 ml/min at 37°C, and the ultraviolet absorption wavelength was set at 210 nm.
Selection of reference compounds
Twenty-three structurally diverse reference drugs were used in developing a rapid screening method for the BBB penetration potential. Of these, β-estradiol, caffeine, chlorpromazine, clonidine, desipramine, ibuprofen, imipramine, progesterone, promazine, propranolol, and testosterone were classified in the literature as "high brain penetration" (CNS+) drugs and aldosterone, atenolol, cefuroxime, cimetidine, corticosterone, enalapril, hydrocortisone, lomefloxacin, loperamide, nadolol, piroxicam, and timolol as "low brain penetration" (CNS-) drugs. 6, 11, 23, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] These literature classifications were based on the measurement of the rate by which the drug enters the brain, the blood-brain distribution under steady state, or the pharmacological activity directly linked to brain penetration. The pKa and PAMPA effective permeability (P e ) values were used as reported in literature. 23, 39 Other physicochemical parameters of log P and PSA were calculated using ACD Software (Advanced Chemistry Development, Toronto, Canada) and JEM software (Molinspiration Cheminformatics, Bratislava, Slovak Republic), respectively.
Determination of IAM partition coefficients
Each drug was dissolved in a mixture of acetonitrile:distilled water (50:50, v/v) at a concentration of 100 µg/ml, and a portion (5 µl) was injected to the chromatograph (n = 3 each). The IAM capacity factor (k IAM ) was calculated as
where t r is the retention time of the drug and t 0 is the hold up time of the column. The capacity factor (k IAM ) is linearly related to the equilibrium IAM partition coefficient (K IAM ):
where V m is the total volume of solvent within the IAM column, V s is the volume of the interphase created by the immobilized phospholipids, and β or V s /V m is the phase ratio for a given column. The equilibrium IAM partition coefficient (K IAM ) reflects the distribution of solutes between stationary and mobile phases. The K IAM may be calculated if V s is known. 40 However, the IAM interfacial thickness is unknown, and it is difficult to accurately measure V s . The equilibrium drug partitioning into fluid membranes is usually a rate-limiting step in drug penetration, and the permeation through membranes (membrane permeability P m ) of a drug absorbed by passive diffusion is directly proportional to the equilibrium membrane partition coefficient (K m ):
where D m and L are the membrane diffusion coefficient of the solute and the membrane thickness (approximately 30 Å for the hydrocarbon domain of the bilayers), respectively. 41, 42 Assuming physical similarities exist between IAM and fluid membranes, the K IAM is analogous to K m : There is a linear relationship between K IAM and K m . 27 The D m may be corrected for the effect of the molecular size on diffusion 41, 43 :
where V is the molar volume of drug molecule and n is a constant. It has been shown that the permeability coefficient, being proportional to the product of the diffusion coefficient and the partition coefficient into the bilayer barrier domain, can be modeled by an equation that combines an empirical relationship for a size selectivity of diffusion, 1/V n . 43 Assuming that the molecular weight (MW) is proportional to V, the 1st approximation of D m is inversely proportional to 1/MW n . Indeed, D m primarily depends on the molecular size (MW, molecular volume) of a drug on the highly ordered hydrocarbon chain region in the membrane bilayer. The membrane permeability (P m ) of a drug following passive diffusion may be expressed based on correction by the molecular size:
In this study, the k IAM was calculated for 23 commercial drugs using the IAM phosphatidylcholine column, and the correlation between the BBB penetration and k IAM /MW n was examined as a function of the power function (n).
Method validation
For a method validation, 7 in-house compounds were orally administered (10-30 mg/kg, IC 50 equivalent doses) to male SD rats (n = 3 each), and blood and brain samples were taken at times when the maximum blood drug concentrations were achieved (1-2 h). The whole-brain tissues were isolated from blood and homogenized. The brain-to-plasma ratio (C brain /C plasma ) was calculated for these compounds as determined at times when maximum plasma concentrations were achieved.
RESULTS AND DISCUSSION

Prediction of CNS penetration potential based on IAM partition coefficients
In this study, the k IAM was determined for 23 reference drugs (MW range, 194-477; Table 1 ). The k IAM values were determined at the mobile phase pH of 5.5 and 7.0. The differentiation between CNS+ and CNS-drugs was made based on k IAM corrected by the molecular size with the power function set at 1, 2, 3, 4, and 5 (k IAM / MW n ; Figs. 1 and 2) . The differentiation was most successful when the power function of the capacity factors (k IAM /MW n ) was set at n = 4 at pH 5.5 (Fig. 1D) , with k IAM /MW 4 values separated into 2 ranges. The CNS-drugs showed a tendency to have k IAM / MW 4 values less than 0.64, whereas the CNS+ drugs exhibited a tendency to have k IAM /MW 4 values greater than 1.01 ( Table 2 ). The range of permeability values (k IAM /MW 4 ) was 1.01 to 9.47 for the CNS+ drugs and less than 0.64 for the CNS-drugs. A mobile phase pH of 5.5 may be useful in predicting the BBB penetration, especially when a simultaneous rapid screening of intestinal absorption potential is needed as the prediction of intestinal absorption was most successful at this pH. 28 A mobile phase pH of 7.0 may also be used in predicting the BBB penetration with relatively high success. These pH values were within the pH range recommended by the column manufacturer. Table 1 shows pK a , Clog P, PSA, k IAM /MW 4 , and P e values together with the literature-reported CNS+ and CNS-classification for 23 reference drugs used in the study. Figures 3 and 4 illustrate the correlation between k IAM /MW 4 with log P and PSA, respectively. Good correlations were observed, with the correlation coefficient (r) being 0.721 and 0.786 at pH 5.5 and 7.0, respectively (Fig. 3) .
Comparison of k IAM /MW 4 with log P, PSA, and PAMPA permeability
The PSA has been previously shown to correlate with human intestinal absorption 44, 45 and BBB penetration. 7 When PSA is applied to a larger and more diverse compound set, however, outliers become more frequent. 45, 46 In this study, good correlations were observed between PSA and k IAM /MW 4 , with the correlation being higher at pH 7.0 than at pH 5.5 (r = 0.930 vs. 0.867; Fig. 4) . The CNS+ drugs were identified as those with PSA < 60 2 and Clog P > 2.2. Similar findings have been observed previously, as PSA values <60 to 70 Å 2 tend to identify CNS+ compounds. 47 The likelihood of CNS activity appears to increase with decreasing PSA values. 48 Figure 5 shows the relationship between k IAM /MW 4 and PAMPA effective permeability. The correlation was examined for a set of 16 compounds selected based on available literature data. A better correlation was observed when the capacity factor was determined at pH 5.5 than at pH 7.0 (r = 0.865 vs. 0.796) across all CNS+ and CNS-drugs (Fig. 5) . The CNS+ drugs showed a tendency of exhibiting P e values >4.7 × 10 -6 cm/s at pH 5.5. Similar observations were also made previously in which PSA values >4.0 × 10 -6 cm/s tended to identify CNS+ compounds. 23 As mentioned earlier, the differentiation between CNS+ and CNS-drugs was most successful when the pH was adjusted to 5.5 with the power function of capacity factors (k IAM /MW n ) set at n = 4. Furthermore, given the pH of the small intestine, the mobile phase pH 5.5 instead of 7.0 is more appropriate when both the intestinal brush border membrane and BBB penetrations are needed to be simultaneously predicted. Nevertheless, considering the pH of the blood, the mobile phase pH of 7.0 with the power function of capacity factors ≥4 may also be useful in predicting solely the BBB penetration.
PAMPA and PSA have been previously used to predict BBB penetration. 7, 23 However, the predictions are unsatisfactory depending on the size and quality of the test compounds included in the data set. 7 The IAM method described in this study may be used as a rapid screening tool for the prediction of BBB permeation, providing high success rate, low cost, and convenience for automation, requiring a small quantity of test compounds. Despite the fact that the brain endothelial and gastrointestinal membranes are the biologic barriers with different physiological functions and physicochemical properties, purely passive diffusion is universal for lipid membranes. 49 As with the earlier model for intestinal absorption (k IAM /MW 2.5 ), 28 the simple model described here (k IAM / MW 4 ) may be valid for passive diffusion processes.
Method validation
The utility of the optimized prediction method was examined for 7 newly synthesized PDE-4 inhibitors ( Table 3) . As seen in Figure 6 , an excellent linear correlation (r = 0.959) was observed between k IAM /MW 4 and in vivo plasma-to-brain concentration ratios. The in vivo data used in this study were obtained by determining concentrations in the whole brain and plasma (C brain /C plasma ), but quantitative predictions were not made. Despite this weakness, the good in vitro/in vivo correlation indicates that the developed prediction method may provide estimates of drug uptake across the BBB. The in vivo BBB is a complex system, and drug penetration may be affected by various brain transport routes. Nevertheless, a qualitative prediction may be possible for the differentiation between CNS+ and CNS-drugs.
CONCLUSIONS
This study was performed to develop a prediction method for BBB penetration potential using IAM capacity factors of 23 structurally diverse drugs determined by IAM chromatography. The correlation between k IAM /MW n and CNS penetration was highest when the power function (n) was set at 4. This study indicates that in vitro IAM capacity factors (k IAM /MW 4 ) may be used to classify drugs as CNS+ and CNS-with a high rate of success. 
